Heartbeam, Inc. · NASDAQ:BEAT
Heartbeam — Q1 2022 Earnings Presentation
18 slides from Heartbeam's earnings presentation, May 12, 2022
Slide 1: Heart Attack Detection
Heart Attack Detection First Quarter 2022 Financial Results Conference Call NASDAQ: BEAT May 12, 2022
Slide 2: Disclaimers
First Quarter 2022 Financial Results Conference Call DISCLAIMERS This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company’s future results of operations and financial position
Slide 3: Agenda
First Quarter 2022 Financial Results Conference Call Agenda • Introduction, Recent Announcements and Market Opportunity Branislav Vajdic • Product Timelines and Updates, and Partnerships Jon Hunt • Model at Scale and Financial Results Rick Brounstein • Closing Summary Branislav Vajdic 30 years of ex
Slide 4: Key First Quarter 2022 and Subsequent Highlights
First Quarter 2022 Financial Results Conference Call Key First Quarter 2022 and Subsequent Highlights • Partnership agreement with LIVMOR Inc. to build a HeartBeam branded version of LIVMOR’s Halo+ FDA cleared turnkey solution for remote patient monitoring (“RPM”) • Professional services agreement w
Slide 5: HeartBeam US Market Opportunity
First Quarter 2022 Financial Results Conference Call HeartBeam US Market Opportunity 6x Bigger Than AFIB Market ~18M* ~8M ~3M AFib Patients Prior MI Patients Total CAD Patients $2 billion $4+ billion $10+ billion 1. National Hospital Ambulatory Medical Care Survey: 2016 Emergency Department Summary
Slide 6: Telehealth Market
First Quarter 2022 Financial Results Conference Call Telehealth Market U.S Telehealth Market ($ in Billions) • Adoption rate of telehealth increased $636 dramatically during COVID-19, especially in cardiology, radiology, behavioral health, and online consultation 32% CAGR • Governments actively deve
Slide 7: HeartBeam Solutions: True Platform Technology
First Quarter 2022 Financial Results Conference Call HEARTBEAM SOLUTIONS TRUE PLATFORM TECHNOLOGY ED solution for more ED accurate MI detection Software Q3 20221 Complete telehealth solution for remote MI monitoring Telehealth Q1 20231 1) Estimated FDA Clearance 7
Slide 8: ED Software Tool Updates
First Quarter 2022 Financial Results Conference Call ED Software Tool Updates • Partnered with LIVMOR Inc., a digital health solutions company, to build a HeartBeam branded version of LIVMOR’s Halo+ FDA cleared turnkey solution for remote patient monitoring (“RPM”) to connect physicians and patients
Slide 9: ED Software Product First Revenues
First Quarter 2022 Financial Results Conference Call ED Software Product First Revenues HeartBeam’s software-only heart attack diagnosis tool for the ED Software licensing business model improves accuracy of MI diagnosis drives $100k/year per ED 93% No change in ED GEN 1 patient workflow Leverages e
Slide 10: ED Software and Telehealth Revenue Opportunity
First Quarter 2022 Financial Results Conference Call ED Software and Gen. 1 Telehealth Revenue Opportunity ED SOFTWARE SOLUTION ED Software GEN 1 TELEHEALTH Telehealth HeartBeam will use its own salesforce HeartBeam will use its own salesforce Excellent alignment w/ CAD patient needs GEN 1 ✓ Utilize
Slide 11: Telehealth Updates
First Quarter 2022 Financial Results Conference Call Telehealth Updates • Partnered with Triple Ring Technologies to co-develop its telehealth complete solution 3D vector Electrocardiogram (ECG) collection device for remote heart attack (MI) monitoring Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023
Slide 12: Telehealth Product Development and Regulatory Plan
First Quarter 2022 Financial Results Conference Call Telehealth Product Development and Regulatory Plan 3D Vector Cardiogram FDA 510(K) Credit card sized Telehealth collection device Predicate devices identified GEN 1 Smartphone app Simple validation study Synthesized baseline + Q3 2022 Q1 2023 Will
Slide 13: Telehealth Product Reimbursement Strategy
First Quarter 2022 Financial Results Conference Call Telehealth Product Reimbursement Strategy Use Available PRM Codes to Accelerate Revenue and Data Collection Basic Gen 1 Utilize existing RPM* Codes Excellent alignment with CPT Codes Coverage PBF** Subscription CAD patient needs Includes the initi
Slide 14: Market Landscape: Substantial Capabilities Beyond Existing Offerings
First Quarter 2022 Financial Results Conference Call Market Landscape Substantial Capabilities Beyond Existing Offerings Heart Attack Detection 12L ECG Capable Integrates history & symptoms Uses Baseline Long Term Use Potential AFib Detection AFlutter Detection 14
Slide 15: Sample Financial Model for ED & Telehealth Solutions at Scale
First Quarter 2022 Financial Results Conference Call Sample Financial Model for our ED & Telehealth Solutions at Scale Revenue at TAM Penetration % Sample Financial Model $25M Sample Financial Model $100M $ in Thousands ED Telehealth Total ED Telehealth Total Telehealth Total Revenue $12,500 $12,500
Slide 16: Q1 2022 Financial Highlights
First Quarter 2022 Financial Results Conference Call Q1 2022 Financial Highlights $ in Thousands Quarters ended March 31, 2022 2021 Operating Expenses: General & Administrative $1,414 $134 Research & Development 734 29 Total Operating Expenses 2,148 163 Loss from Operations (2,148) (163) Interest In
Slide 17: Closing Summary
First Quarter 2022 Financial Results Conference Call Closing Summary • Well known and previously unsolved problem with a massive worldwide market • Product timeline and milestones on track for FDA Clearance and market launch • Initiated strategic partnerships to advance Emergency Department (ED) Myo
Slide 18: Q&A
Q&A Company Investor Relations Rick Brounstein Chris Tyson Chief Financial Officer Executive Vice President HeartBeam, Inc. MZ North America ir@heartbeam.com Direct: 949-491-8235 BEAT@mzgroup.us www.mzgroup.us www.heartbeam.com 2118 Walsh Avenue, Suite 210 Santa Clara, CA 95050